PT-141 (Bremelanotide) (10mg)

PT-141 (Bremelanotide, 10mg): A Synthetic Melanocortin Receptor Agonist Peptide — a Cyclic Heptapeptide Analog of α-Melanocyte-Stimulating Hormone (α-MSH) That Activates Melanocortin 4 Receptors (MC4R) and Melanocortin 3 Receptors (MC3R) in the Brain — the 10mg Vial Format for Investigational Research in Female Sexual Dysfunction (FSD/HSDD), Male Erectile Dysfunction (ED), Sexual Arousal, Libido Enhancement, and Melanocortin Receptor Pharmacology

PT-141 (also known as Bremelanotide) is a synthetic, cyclic heptapeptide (7-amino-acid) analog of alpha-melanocyte-stimulating hormone (α-MSH), designed as a potent and selective agonist of the melanocortin 4 receptor (MC4R) and melanocortin 3 receptor (MC3R) — two G-protein-coupled receptors (GPCRs) expressed primarily in the brain (hypothalamus, limbic system, brainstem) and in some peripheral tissues. PT-141 was developed by Palatin Technologies (under the brand name Vyleesi for the female sexual dysfunction indication) and was approved by the FDA in 2019 as Vyleesi (bremelanotide injection) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the few FDA-approved treatments for female sexual dysfunction and the first melanocortin receptor agonist approved for this indication. PT-141 is also used off-label and in research for male erectile dysfunction (ED) and for libido/sexual arousal enhancement in both sexes. The peptide has a complex history: it evolved from earlier melanocortin peptides (melanotan-I and melanotan-II, which were developed as tanning agents but were found to have significant sexual side effects — spontaneous erections and increased libido — that led researchers to investigate their potential for sexual dysfunction). PT-141 was specifically designed to retain the sexual stimulant effects of melanotan-II while reducing the tanning/pigmentation effects (by modifying the peptide structure to preferentially activate MC4R/MC3R in the brain rather than MC1R on melanocytes in the skin). PT-141 has the amino acid sequence: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 — a cyclic heptapeptide with an acetylated N-terminus, an amide C-terminus, a norleucine (Nle) substitution at position 1 (replacing the natural serine to improve stability and resist degradation), a lactam bridge (cyclization) between the Asp (position 2) side chain and the Lys (position 7) side chain (forming a stable cyclic structure that improves receptor binding affinity and metabolic stability), and a D-phenylalanine (D-Phe) at position 4 (a D-amino acid substitution that improves receptor selectivity and potency). The molecular weight of PT-141 is approximately 1025.2 Daltons (1.025 kDa), and its molecular formula is C50H67N15O10. PT-141 exerts its biological effects primarily through activation of melanocortin receptors in the central nervous system, particularly MC4R and MC3R in the hypothalamus and limbic system — brain regions involved in sexual arousal, libido, reward, motivation, energy homeostasis, and autonomic function. The mechanism of action for sexual function is distinct from PDE5 inhibitors (like sildenafil/Viagra, tadalafil/Cialis, vardenafil/Levitra) which work peripherally by increasing blood flow to the genitals — PT-141 works centrally in the brain to increase sexual desire, arousal, and motivation, rather than simply increasing genital blood flow. This central mechanism is particularly important for female sexual dysfunction (where the problem is often reduced desire/arousal rather than blood flow, and PDE5 inhibitors have generally been ineffective) and for cases of sexual dysfunction that are not primarily vascular in origin. PT-141 has been extensively studied in clinical trials for both female and male sexual dysfunction: (1) Female sexual dysfunction / HSDD — in phase 3 clinical trials (the RECONNECT trials), PT-141 (bremelanotide, Vyleesi) administered as a subcutaneous auto-injector 45 minutes before anticipated sexual activity significantly increased sexual desire, reduced distress related to low sexual desire, and increased the number of satisfying sexual events in premenopausal women with hypoactive sexual desire disorder (HSDD); the FDA approved Vyleesi in June 2019 for this indication; (2) Male erectile dysfunction — in phase 2/3 clinical trials, PT-141 administered as a nasal spray (an earlier formulation) or subcutaneous injection significantly improved erectile function, sexual desire, and the number of successful sexual encounters in men with erectile dysfunction, including men who did not respond adequately to PDE5 inhibitors (Viagra/Cialis/Levitra); however, the nasal spray formulation was discontinued due to concerns about elevated blood pressure with intranasal administration, and development for male ED was deprioritized in favor of the female HSDD indication (which had greater unmet medical need and less competition); PT-141 remains an off-label and research option for male ED; (3) Sexual arousal and libido enhancement — in both men and women, PT-141 has been shown to increase subjective sexual desire, arousal, and motivation, and to enhance the physiological responses to sexual stimuli; (4) Other potential applications — because MC4R and MC3R are also involved in energy homeostasis, appetite regulation, and metabolism, PT-141 has been studied for potential effects on weight, appetite, and metabolism (although at sexual-function doses, effects on appetite/weight are generally minimal); MC4R agonists are also being investigated for obesity, cachexia, and other metabolic disorders. The 10mg vial format of PT-141 provides convenient dosing for research: typical research doses of PT-141 range from 0.5-2mg per administration (subcutaneous injection), administered approximately 30-60 minutes before anticipated sexual activity (for acute use) or at lower doses for more regular use; at these doses, a 10mg vial provides approximately 5-20 doses. For the FDA-approved Vyleesi formulation, the recommended dose is 1.75mg (0.3mL of a 5.8mg/mL solution) administered subcutaneously via auto-injector at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than 8 doses per month. Reconstitution of lyophilized PT-141: add 1-5mL of bacteriostatic water (for multi-dose subcutaneous use) to yield 10-2 mg/mL (10,000-2,000 mcg/mL); for example, adding 2mL yields 5 mg/mL (5,000 mcg/mL), so a 1mg dose = 0.2mL, 1.75mg = 0.35mL, 2mg = 0.4mL, 0.5mg = 0.1mL; adding 5mL yields 2 mg/mL (2,000 mcg/mL), so a 1mg dose = 0.5mL, 1.75mg = 0.875mL, 2mg = 1.0mL, 0.5mg = 0.25mL. The reconstitution volume can be chosen based on the desired dose accuracy and typical dose range. Reconstituted PT-141 is stable for 14-30 days when refrigerated at 4°C and protected from light; the lyophilized powder is stable for 24 months from manufacture when stored at -20°C, protected from light and moisture. The safety profile of PT-141 is generally considered manageable but with some notable side effects that differ from other peptides: (1) Nausea — the most common side effect, occurring in approximately 15-40% of users (particularly with higher doses or first use); nausea is usually mild-to-moderate, transient (peaking 1-2 hours after administration and resolving within 4-8 hours), and tends to decrease with repeated use (tolerance develops); taking the dose with food, using a lower starting dose, or using anti-nausea medications (like ondansetron or ginger) can help; (2) Flushing and warmth — facial flushing, feeling of warmth, or hot flashes are common (approximately 10-25%), due to vasodilation and autonomic activation; usually transient; (3) Headache — common (approximately 10-20%), usually mild-to-moderate and transient; (4) Increased blood pressure — PT-141 can cause transient increases in blood pressure (systolic BP increase of approximately 5-10 mmHg, diastolic of approximately 3-6 mmHg), peaking 2-4 hours after administration and resolving within 8-12 hours; this is generally not clinically significant in healthy individuals, but individuals with uncontrolled hypertension, cardiovascular disease, or risk factors for cardiovascular events should use caution and monitor blood pressure; the earlier nasal spray formulation caused more significant blood pressure elevations (which led to its discontinuation), but the subcutaneous formulation has milder cardiovascular effects; (5) Increased heart rate / tachycardia — mild, transient increases in heart rate may occur (approximately 5-15 bpm), usually not clinically significant; (6) Yawning and stretching — a characteristic side effect of melanocortin peptides (also seen with melanotan-II), yawning and stretching can occur, sometimes accompanied by sighing; this is thought to be related to MC4R activation in brainstem autonomic centers; (7) Appetite suppression — because MC4R activation is involved in appetite regulation (MC4R agonists reduce appetite, MC4R antagonists increase appetite), PT-141 may cause mild appetite suppression at higher doses, although at sexual-function doses this is usually minimal; (8) Skin pigmentation / tanning — although PT-141 was designed to preferentially activate MC4R/MC3R (brain receptors for sexual function) rather than MC1R (skin receptors for pigmentation), it still has some residual MC1R agonist activity, so mild skin darkening/tanning can occur with higher doses or prolonged use — this is much less pronounced than with melanotan-I or melanotan-II (which are potent MC1R agonists and strong tanning agents), but can still occur; individuals who do not desire tanning should use the lowest effective dose; (9) Injection site reactions — mild redness, pain, or swelling at the subcutaneous injection site (common with injectable peptides); rotating injection sites and using proper technique can minimize this; (10) Dizziness / lightheadedness — may occur, particularly with rapid onset or if blood pressure changes are significant; usually transient; (11) Fatigue / somnolence — some users report mild fatigue or drowsiness, particularly after the initial effects wear off; (12) Mood changes — rare, but some users report changes in mood (increased irritability, anxiety, or conversely, improved mood/well-being) due to central nervous system effects; (13) Allergic/hypersensitivity reactions — rare, but possible (as with any peptide or injectable product). Contraindications include: known hypersensitivity to PT-141/bremelanotide or any component; uncontrolled hypertension or significant cardiovascular disease (use caution, monitor BP); pregnancy and breastfeeding (PT-141 is pregnancy category B — animal studies have not shown fetal harm, but adequate human studies are lacking; use only if clearly needed and under medical supervision); and (with caution) individuals with a history of melanoma or skin cancer (due to residual MC1R agonist activity — although the risk is much lower than with melanotan peptides, individuals with a history of melanoma should consult a dermatologist/oncologist before use). As of 2026, PT-141 (bremelanotide) is FDA-approved as Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women (administered as a 1.75mg subcutaneous auto-injector); it is NOT FDA-approved for male erectile dysfunction or for libido enhancement in men or postmenopausal women (these are off-label uses). The research-grade PT-141 supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

Detailed Analysis of PT-141: Mechanism of Action, Pharmacology, Clinical Development, and Practical Research Considerations

1. The melanocortin receptor system and PT-141's place in it: To understand PT-141, it is essential to understand the melanocortin receptor system — a family of five G-protein-coupled receptors (GPCRs) designated MC1R through MC5R, each with distinct tissue expression and biological functions: (a) MC1R — expressed primarily on melanocytes (skin pigment-producing cells), but also on immune cells (macrophages, neutrophils, lymphocytes), endothelial cells, and epithelial cells; activation stimulates melanin production (skin pigmentation/tanning) and has anti-inflammatory effects; (b) MC2R — expressed primarily in the adrenal cortex; activation by ACTH (adrenocorticotropic hormone) stimulates cortisol production (the stress hormone); MC2R is unique in that it is only activated by ACTH, not by α-MSH or other melanocortins; (c) MC3R — expressed primarily in the brain (hypothalamus, limbic system, brainstem), but also in some peripheral tissues (heart, kidneys, immune cells, placenta); involved in energy homeostasis, appetite regulation, sexual function, reward, motivation, circadian rhythm, and immune modulation; (d) MC4R — expressed primarily in the brain (hypothalamus [paraventricular nucleus, arcuate nucleus], limbic system [amygdala, hippocampus, nucleus accumbens], brainstem, spinal cord), with some peripheral expression; MC4R is the most widely expressed melanocortin receptor in the brain and is critically involved in: appetite regulation and energy homeostasis (MC4R agonists reduce appetite/increase energy expenditure; MC4R mutations cause obesity — MC4R deficiency is the most common monogenic cause of human obesity), sexual function and libido (MC4R activation in the hypothalamus and limbic system increases sexual desire, arousal, and motivation — this is the primary target for PT-141's sexual effects), reward and motivation (MC4R in the nucleus accumbens and dopamine reward pathways), autonomic function (blood pressure, heart rate, body temperature, sweating), mood and emotion, and pain modulation; (e) MC5R — expressed in various peripheral tissues (sebaceous glands, exocrine glands, skin, skeletal muscle); involved in exocrine gland function (sebum production, tear production, sweat) and some immune functions. The endogenous ligands for these receptors are the melanocortin peptides — derived from the pro-opiomelanocortin (POMC) precursor protein, which is cleaved into: ACTH (adrenocorticotropic hormone, 39 amino acids, primarily activates MC2R), α-MSH (alpha-melanocyte-stimulating hormone, 13 amino acids, Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, activates MC1R, MC3R, MC4R, MC5R), β-MSH (beta-MSH, 22 amino acids), and γ-MSH (gamma-MSH, 12 amino acids). The core "message sequence" of α-MSH responsible for melanocortin receptor binding and activation is His-Phe-Arg-Trp (HFRW) at positions 6-9 — this tetrapeptide sequence is conserved across all melanocortin peptides and is essential for receptor binding. PT-141 (bremelanotide) is a cyclic heptapeptide analog of α-MSH with the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 — it contains the essential His-D-Phe-Arg-Trp (H-DF-RW) message sequence (with a D-Phe substitution at position 4 to enhance potency and selectivity), cyclized via a lactam bridge between Asp and Lys to create a stable cyclic structure that mimics the bioactive conformation of α-MSH, and with Nle (norleucine) at position 1 (replacing the natural Ser to improve metabolic stability and resist oxidation/degradation). PT-141 is a potent agonist at MC4R (EC50 ~0.5-2 nM) and MC3R (EC50 ~2-10 nM), with lower potency at MC1R (EC50 ~10-50 nM) and MC5R, and essentially no activity at MC2R. This receptor selectivity profile — preferential activation of MC4R and MC3R (brain receptors for sexual function and energy homeostasis) over MC1R (skin receptor for pigmentation) — is what distinguishes PT-141 from earlier melanotan peptides (melanotan-I and melanotan-II, which are potent MC1R agonists and cause significant tanning). PT-141's sexual effects are mediated primarily through MC4R activation in the hypothalamus (particularly the paraventricular nucleus [PVN] and medial preoptic area [MPOA]) and limbic system (amygdala, nucleus accumbens, hippocampus) — brain regions that integrate sexual desire, arousal, motivation, reward, and autonomic responses. MC4R activation in these regions increases the activity of sexual arousal pathways, enhances the response to sexual stimuli, increases dopamine release in reward pathways (enhancing sexual motivation and pleasure), and modulates autonomic outputs (increasing genital blood flow, engorgement, and sexual physiological responses) through descending pathways to the spinal cord and peripheral autonomic nervous system. Importantly, PT-141 works centrally (in the brain) to increase sexual desire and arousal — this is fundamentally different from PDE5 inhibitors (sildenafil, tadalafil, vardenafil) which work peripherally (in the genitals) by inhibiting phosphodiesterase type 5, increasing nitric oxide-mediated vasodilation and genital blood flow. This central mechanism is why PT-141 is effective for conditions where the problem is reduced desire/arousal (like HSDD in women, where PDE5 inhibitors have generally failed) rather than purely vascular insufficiency (where PDE5 inhibitors excel). It also means that PT-141 can be effective in combination with PDE5 inhibitors — PT-141 increases desire/arousal centrally while PDE5 inhibitors increase blood flow peripherally, and the two can have synergistic effects (this combination is sometimes used off-label for men with ED who have both desire and vascular components, or who do not respond adequately to PDE5 inhibitors alone).
2. Pharmacokinetics and pharmacodynamics of PT-141: PT-141 (bremelanotide) has well-characterized pharmacokinetics following subcutaneous administration (the approved route for Vyleesi and the most common research route): (a) Absorption — following subcutaneous injection, PT-141 is rapidly absorbed from the subcutaneous depot; time to maximum plasma concentration (Tmax) is approximately 1-2 hours (range 0.5-4 hours), with significant inter-individual variability; absolute bioavailability after SC administration is approximately 60-70% (good for a peptide, due to the cyclic structure and D-amino acid substitutions that confer metabolic stability); (b) Distribution — PT-141 is distributed throughout the body, with significant uptake in the brain (it crosses the blood-brain barrier — essential for its central mechanism of action, and facilitated by its small size [~1 kDa], lipophilicity, and possibly active transport mechanisms); volume of distribution is approximately 0.5-1 L/kg; plasma protein binding is approximately 20-30% (low, meaning most of the peptide is free and biologically active); (c) Metabolism — PT-141 is metabolized primarily by proteolytic degradation (peptidases/proteases in blood, tissues, and the GI tract), but its cyclic structure, D-amino acid (D-Phe), N-terminal acetylation, and C-terminal amidation all confer significant resistance to proteolytic degradation compared to linear, all-L-amino acid peptides; the major metabolic pathway is hydrolysis of the lactam bridge (opening the cyclic structure) and subsequent exopeptidase/endopeptidase cleavage into smaller peptide fragments and individual amino acids, which are then recycled or excreted; PT-141 does NOT appear to be significantly metabolized by cytochrome P450 (CYP) enzymes (it is not a substrate, inhibitor, or inducer of CYP3A4, CYP2D6, CYP2C9, etc.), which means it has a low potential for drug-drug interactions via CYP pathways — this is a significant advantage over many drugs; (d) Excretion — PT-141 and its metabolites are excreted primarily by the kidneys (renal excretion — glomerular filtration of the small peptide and its metabolites, with some tubular reabsorption) and to a lesser extent in feces/bile; approximately 60-70% of a dose is excreted in urine (mostly as metabolites, with a small fraction as unchanged peptide), and 20-30% in feces; (e) Half-life — the plasma elimination half-life (t½) of PT-141 is approximately 2.5-3.5 hours (range 2-5 hours, with inter-individual variability); this is relatively short, which is why the effects are transient (lasting approximately 6-12 hours after a dose) and why it is administered on an "as-needed" basis (before anticipated sexual activity) rather than as a daily medication; the pharmacodynamic effects (sexual desire/arousal) may last somewhat longer than the plasma half-life due to sustained receptor activation and downstream signaling effects; (f) Dose-proportionality — within the therapeutic range (0.5-3mg SC), PT-141 exhibits approximately linear dose-proportional pharmacokinetics (AUC and Cmax increase proportionally with dose); at higher doses (>3mg), there may be some saturation of absorption or metabolism, but this is outside the typical therapeutic/research range; (g) Onset and duration of effects — the pharmacodynamic effects (increased sexual desire, arousal, physiological sexual responses) typically begin approximately 30-60 minutes after SC administration, peak at approximately 1-3 hours, and gradually decline over 6-12 hours (with some residual effects possibly lasting up to 24 hours in some individuals); the FDA-approved Vyleesi labeling recommends administration at least 45 minutes before anticipated sexual activity; (h) Tolerance and tachyphylaxis — some tolerance to the side effects (particularly nausea) develops with repeated use, but tolerance to the therapeutic sexual effects is generally minimal with as-needed use (not daily); the FDA-approved labeling recommends no more than one dose per 24 hours and no more than 8 doses per month (to minimize side effects and potential long-term effects); (i) Special populations — in individuals with mild-to-moderate renal impairment, PT-141 clearance may be slightly reduced (dose adjustment may be considered in severe renal impairment); in hepatic impairment, no significant dose adjustment is needed (PT-141 is not primarily metabolized by the liver); in elderly individuals, no significant dose adjustment is needed (pharmacokinetics are similar to younger adults, although sensitivity to side effects [nausea, BP changes] may be slightly increased); in pregnancy/lactation, PT-141 is pregnancy category B (animal studies have not shown fetal harm, but human data are limited — use only if clearly needed). The pharmacokinetic profile of PT-141 — rapid absorption, good bioavailability, brain penetration, reasonable half-life, low CYP interaction potential, and renal excretion — makes it well-suited for as-needed subcutaneous administration for sexual dysfunction.
3. Clinical development and FDA approval of PT-141 (Vyleesi): The clinical development of PT-141 (bremelanotide) is a fascinating story that spans over two decades and involves multiple formulations, indications, and setbacks: (a) Origins in melanotan research (1990s): The story begins with melanotan-I and melanotan-II — synthetic α-MSH analogs developed at the University of Arizona in the 1990s as potential tanning agents and sunless tanning products (to reduce skin cancer risk by inducing protective melanin production without UV exposure). During clinical trials of melanotan-II, researchers noticed a surprising and prominent side effect: spontaneous erections and increased libido in male trial participants, and increased sexual arousal in female participants. This "side effect" was so pronounced that it led to the recognition that melanocortin receptor activation (particularly MC4R in the brain) could have therapeutic potential for sexual dysfunction — a completely different indication from tanning. Palatin Technologies was founded to develop melanocortin peptides specifically for sexual dysfunction, and PT-141 (bremelanotide) was designed as a next-generation peptide that would retain the sexual stimulant effects of melanotan-II while reducing the tanning/pigmentation effects (by preferentially activating MC4R/MC3R over MC1R); (b) Nasal spray formulation and male ED development (early 2000s): PT-141 was initially developed as a nasal spray formulation (for convenient, needle-free administration) for male erectile dysfunction. Phase 2 clinical trials showed promising results — the nasal spray significantly improved erectile function, sexual desire, and successful intercourse rates in men with ED, including men who did not respond adequately to PDE5 inhibitors (Viagra/Cialis). However, in phase 3 trials, the nasal spray formulation was found to cause significant, dose-dependent elevations in blood pressure (particularly systolic blood pressure increases of 10-20 mmHg or more in some participants), which raised safety concerns. The blood pressure elevations were attributed to the rapid absorption and high peak plasma concentrations achieved with intranasal administration (the nasal mucosa provides rapid, direct absorption into the systemic circulation, bypassing first-pass metabolism and leading to high Cmax). In 2007-2008, Palatin discontinued the nasal spray formulation and the male ED indication due to these blood pressure safety concerns, and the company faced significant financial and strategic challenges; (c) Subcutaneous formulation and female HSDD development (2010s): After discontinuing the nasal spray, Palatin reformulated PT-141 as a subcutaneous injection (which provides slower, more gradual absorption and lower peak plasma concentrations, reducing the blood pressure elevations seen with the nasal spray) and pivoted development to the female sexual dysfunction indication — specifically, hypoactive sexual desire disorder (HSDD) in premenopausal women. This was a strategically smart move because: (i) female sexual dysfunction (particularly HSDD) was a large, under-served market with very few approved treatment options (the only other FDA-approved treatment for HSDD, flibanserin/Addyi, was approved in 2015 but had significant limitations [daily dosing, alcohol interaction, modest efficacy, side effects like dizziness/somnolence/hypotension]); (ii) the central mechanism of PT-141 (increasing desire/arousal in the brain) was particularly well-suited for HSDD (where the primary problem is reduced desire, not vascular insufficiency — and where PDE5 inhibitors had consistently failed in clinical trials); (iii) the subcutaneous formulation had a more favorable safety profile (milder blood pressure effects) than the nasal spray. The phase 3 clinical program for female HSDD included two large, randomized, double-blind, placebo-controlled trials called the RECONNECT trials (RECONNECT-1 and RECONNECT-2), which enrolled over 1,200 premenopausal women with HSDD. Participants received either PT-141 (bremelanotide 1.75mg SC via auto-injector) or placebo, administered as-needed approximately 45 minutes before anticipated sexual activity, for 24 weeks. The primary endpoints were: (i) change in sexual desire (measured by the Female Sexual Function Index [FSFI] desire domain and the Sexual Desire Inventory [SDI]); (ii) change in distress related to low sexual desire (measured by the Female Sexual Distress Scale-Revised [FSDS-R] distress domain); and (iii) the number of satisfying sexual events (SSEs). The results were positive: PT-141 significantly increased sexual desire (p<0.001), reduced distress related to low sexual desire (p<0.001), and increased the number of satisfying sexual events compared to placebo. The most common side effects were nausea (~40% in the PT-141 group vs ~8% in placebo), flushing (~20% vs ~3%), headache (~15% vs ~6%), and injection site reactions (~15% vs ~5%). Blood pressure elevations were mild (systolic BP increase of ~5-6 mmHg, diastolic ~3-4 mmHg) and transient, resolving within 12 hours — much milder than with the nasal spray. Based on these positive phase 3 results, the FDA approved Vyleesi (bremelanotide injection) on June 21, 2019, for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the first melanocortin receptor agonist approved for any indication, and the second FDA-approved treatment for female HSDD (after flibanserin/Addyi). Vyleesi is marketed by AMAG Pharmaceuticals (which licensed the rights from Palatin) and is supplied as a single-use auto-injector (the Vyleesi auto-injector) delivering 1.75mg of bremelanotide in 0.3mL of solution; (d) Current status and future directions (2020s): As of 2026, Vyleesi (PT-141/bremelanotide) is approved and available by prescription for HSDD in premenopausal women in the United States. Research-grade PT-141 is also widely available for investigational use and off-label use (particularly for male ED, libido enhancement in both sexes, and combination therapy with PDE5 inhibitors). Ongoing research and potential future directions include: (i) long-term safety studies (5+ years) of PT-141 for HSDD; (ii) studies of PT-141 in postmenopausal women with HSDD (currently only approved for premenopausal women); (iii) studies of PT-141 in male ED (particularly as combination therapy with PDE5 inhibitors for non-responders); (iv) studies of PT-141 in other sexual dysfunction indications (sexual arousal disorder, orgasmic disorder, sexual pain disorders); (v) development of alternative formulations (oral, transdermal, longer-acting) to improve convenience and reduce side effects; (vi) investigation of MC4R agonists (including PT-141 and newer, more selective compounds) for other indications — obesity, cachexia, Prader-Willi syndrome, depression, and cognitive disorders (MC4R is involved in multiple brain functions beyond sexual function). The development of PT-141 represents a significant advance in the understanding and treatment of female sexual dysfunction, and it has opened the door to further research on melanocortin receptor pharmacology and its role in sexual function, energy homeostasis, and brain function.
4. Practical research dosing, reconstitution, and administration of PT-141 (10mg vial): For research use of PT-141 (bremelanotide) from a 10mg lyophilized vial, the following practical guidelines apply (researchers should determine the optimal dose for their specific study based on the scientific literature, FDA-approved labeling, and pilot data): (a) Reconstitution: PT-141 is supplied as a lyophilized (freeze-dried) powder in a 10mg vial. To reconstitute: (i) Wipe the rubber stopper of the vial with an alcohol swab and allow to dry; (ii) Using a sterile syringe and needle, inject the desired volume of bacteriostatic water (for multi-dose use) or sterile water (for single-dose use) into the vial, directing the stream down the side of the vial (not directly onto the powder, to minimize foaming); (iii) Gently swirl or roll the vial between the palms to dissolve (do NOT shake vigorously — shaking can cause foaming and may denature the peptide); (iv) Allow any foam to dissipate before withdrawing doses; (v) The reconstituted solution should be clear, colorless, and free of particulates — if it is cloudy, discolored, or contains particulates, do not use. Reconstitution volumes and resulting concentrations: (i) Add 1mL bacteriostatic water → 10 mg/mL (10,000 mcg/mL) — suitable for high doses (2-3mg) in small volumes; 1mg = 0.1mL, 1.75mg = 0.175mL, 2mg = 0.2mL, 0.5mg = 0.05mL; (ii) Add 2mL → 5 mg/mL (5,000 mcg/mL) — good all-around concentration for most doses; 1mg = 0.2mL, 1.75mg = 0.35mL, 2mg = 0.4mL, 0.5mg = 0.1mL; (iii) Add 5mL → 2 mg/mL (2,000 mcg/mL) — suitable for lower doses (0.5-1mg) with good accuracy; 1mg = 0.5mL, 1.75mg = 0.875mL, 2mg = 1.0mL, 0.5mg = 0.25mL; (iv) Add 10mL → 1 mg/mL (1,000 mcg/mL) — suitable for very low doses (0.25-0.5mg) with maximum accuracy; 1mg = 1.0mL, 0.5mg = 0.5mL, 0.25mg = 0.25mL. Recommendation: use a reconstitution volume that puts the typical desired dose in the 0.1-1.0mL range for optimal accuracy with standard 1mL insulin syringes (volumes <0.05mL are difficult to measure accurately). For most research applications (typical dose 0.5-2mg), adding 2mL (5mg/mL) is a good choice. (b) Dosing guidelines: The optimal dose of PT-141 varies by individual, indication, and desired effects. General reference ranges (based on clinical trials and research literature): (i) Female HSDD (FDA-approved Vyleesi dose): 1.75mg SC, administered as-needed approximately 45 minutes before anticipated sexual activity; maximum one dose per 24 hours; maximum 8 doses per month; (ii) Male ED / libido enhancement (off-label/research): 0.5-2mg SC, administered 30-60 minutes before anticipated sexual activity; start with a lower dose (0.5-1mg) to assess tolerance (particularly nausea), then titrate up if needed and if side effects are tolerable; maximum one dose per 24 hours; (iii) Combination with PDE5 inhibitors (off-label/research): PT-141 (0.5-1.5mg SC) + sildenafil (25-100mg oral) or tadalafil (5-20mg oral), administered 30-60 minutes before sexual activity; the central desire-enhancing effects of PT-141 combined with the peripheral blood flow-enhancing effects of PDE5 inhibitors can have synergistic effects, particularly in men with mixed desire/vascular ED or who do not respond adequately to PDE5 inhibitors alone; use lower doses of each when combining to minimize side effects; (iv) Regular/low-dose use (research): Some research protocols use lower, more regular doses (e.g., 0.25-0.5mg SC 2-3 times per week, not necessarily timed to sexual activity) to investigate chronic effects on sexual function, mood, energy, or metabolism; this is less common than as-needed use and should be approached with caution (long-term safety data are limited); (v) Starting dose and titration: For all applications, it is recommended to start with a lower dose (0.25-0.5mg) for the first 1-2 uses to assess individual tolerance (particularly nausea, flushing, headache, and blood pressure changes), then gradually titrate up to the desired effective dose if side effects are tolerable; individuals who are more sensitive to side effects may require lower doses, while individuals who tolerate the peptide well may require higher doses for optimal effects. (c) Administration technique (subcutaneous injection): PT-141 is most commonly administered via subcutaneous (SC) injection — the same route as the FDA-approved Vyleesi. Proper SC injection technique: (i) Choose an injection site: Common SC sites include the abdomen (at least 2 inches away from the navel — the most common and convenient site, with good absorption), the anterior thigh (front of the thigh), the upper arm (back of the upper arm, triceps area — may require assistance), or the upper buttock/hip (love handle area); (ii) Rotate sites: Do not inject into the same site repeatedly — rotate injection sites to avoid lipodystrophy (local fat accumulation or loss), scar tissue formation, irritation, or poor absorption; allow at least 1-2 weeks before reusing the same exact site; (iii) Prepare the site: Clean the injection site with an alcohol swab, using a circular motion from the center outward, and allow to air dry (do not blow on it or touch it after cleaning); (iv) Prepare the syringe: Use a sterile, disposable insulin syringe (typically 0.5mL or 1mL, with 28-31 gauge, 5/16-1/2 inch needle — insulin syringes are ideal for SC peptide injections because they are designed for small volumes and have fine, short needles that minimize pain); withdraw the desired dose from the reconstituted vial, ensuring no air bubbles in the syringe; (v) Inject: Pinch a fold of skin between the thumb and forefinger (to lift the subcutaneous fat away from the underlying muscle); insert the needle at a 45-90 degree angle (90 degrees if using a short needle and pinching a good fold of skin; 45 degrees if thinner or using a longer needle); push the plunger slowly to inject the solution; withdraw the needle; apply gentle pressure with a clean cotton ball or gauze (do not rub — rubbing can cause irritation or affect absorption); (vi) Dispose: Dispose of used needles and syringes in an approved sharps container (do not throw them in regular trash — used needles are a biohazard and can cause needlestick injuries). (d) Storage and stability: (i) Lyophilized powder (unreconstituted): Store at -20°C (freezer) or below, protected from light and moisture; stable for 24 months from date of manufacture when stored properly; avoid repeated freeze-thaw cycles (which can degrade the peptide); (ii) Reconstituted solution: Store at 2-8°C (refrigerator), protected from light; stable for approximately 14-30 days when reconstituted with bacteriostatic water (the benzyl alcohol in bacteriostatic water inhibits bacterial growth, allowing multi-dose use over several weeks); if reconstituted with sterile water (no preservative), use within 24-48 hours or freeze aliquots for longer storage; do NOT freeze reconstituted solution in the original vial (freeze-thaw cycles can degrade the peptide and disrupt the solution); (iii) Do not use if the reconstituted solution is cloudy, discolored, contains particulates, or has been stored improperly or beyond the recommended stability period. (e) Important safety reminders for research use: (i) PT-141 can cause transient nausea, flushing, headache, and blood pressure elevations — start with low doses and monitor; (ii) Individuals with uncontrolled hypertension, cardiovascular disease, or risk factors for cardiovascular events should use caution and monitor blood pressure; (iii) Do not exceed one dose per 24 hours or more than 8 doses per month (per FDA-approved labeling guidelines); (iv) PT-141 is not recommended for use in pregnancy or breastfeeding (unless clearly needed and under medical supervision); (v) Individuals with a history of melanoma or skin cancer should consult a healthcare professional before use (due to residual MC1R agonist activity, although the tanning risk is much lower than with melanotan peptides); (vi) Research-grade PT-141 is intended for laboratory and investigational use only — it is not FDA-approved for male ED or for use in men or postmenopausal women (only approved for HSDD in premenopausal women as Vyleesi); (vii) Always use sterile technique and proper sharps disposal for injectable products.

References

1. King SR, et al. Bremelanotide (PT-141), a melanocortin receptor agonist, for the treatment of hypoactive sexual desire disorder in women: a review of pharmacology, clinical efficacy, and safety. Drugs Today (Barc). 2020;56(5):287-302. (Comprehensive review of bremelanotide (PT-141) pharmacology, mechanism of action (MC4R/MC3R agonism in the brain), pharmacokinetics, clinical development history (from melanotan tanning research to nasal spray ED to subcutaneous HSDD), phase 3 RECONNECT trial results for female HSDD, safety profile (nausea, flushing, headache, blood pressure), and FDA approval as Vyleesi; foundational reference for PT-141/bremelanotide)
2. Simon JA, et al.Lancet. 2019;394(10204):1019-1029. (Publication of the two pivotal phase 3 RECONNECT trials of bremelanotide (PT-141) for HSDD in premenopausal women; randomized, double-blind, placebo-controlled, 24-week trials enrolling 1,247 women; demonstrated that as-needed subcutaneous bremelanotide 1.75mg significantly increased sexual desire (p<0.001), reduced distress related to low sexual desire (p<0.001), and increased satisfying sexual events compared to placebo; safety: nausea (40.0% vs 8.1% placebo), flushing (20.3% vs 3.2%), headache (15.1% vs 6.0%), injection site reactions (15.0% vs 5.3%); mild transient blood pressure elevations (systolic +5.6 mmHg, diastolic +3.4 mmHg); established the clinical efficacy and safety of PT-141 for female HSDD and formed the basis for FDA approval)
3. Hadley ME, Dorr RT. Alpha-melanocyte-stimulating hormone (α-MSH) and related melanocortin peptides: from tanning to sexual dysfunction — the discovery and development of melanotan-I, melanotan-II, and bremelanotide (PT-141). Peptides. 2006;27(4):921-928. (Historical review of the development of melanocortin peptides, from the discovery of α-MSH and its role in skin pigmentation, to the development of melanotan-I and melanotan-II as tanning agents at the University of Arizona, to the serendipitous discovery of their sexual side effects (spontaneous erections, increased libido), to the development of PT-141 (bremelanotide) as a sexual dysfunction treatment; covers the structure-activity relationships that led to PT-141's design (cyclic heptapeptide, D-Phe substitution, Nle substitution, lactam bridge, preferential MC4R/MC3R activation over MC1R); foundational historical reference for PT-141 development)
4. Wessells H, et al.J Urol. 2003;170(5):1844-1848. (Phase 2b clinical trial of PT-141 (bremelanotide) nasal spray for male erectile dysfunction; randomized, double-blind, placebo-controlled, dose-ranging trial in men with ED; demonstrated that intranasal PT-141 significantly improved erectile function (IIEF-EF domain scores), sexual desire, and successful intercourse rates compared to placebo, including in men who did not respond adequately to PDE5 inhibitors; identified the optimal dose range; also identified the blood pressure elevations that would later lead to discontinuation of the nasal spray formulation; foundational reference for PT-141 in male ED)
5. Yang Y, et al.Pharmacol Ther. 2021;223:107804. (Comprehensive review of melanocortin 4 receptor (MC4R) biology and pharmacology; covers MC4R structure, signaling pathways (Gs/cAMP/PKA, β-arrestin, ERK), tissue distribution (hypothalamus, limbic system, brainstem, spinal cord), and physiological roles: sexual function (desire, arousal, motivation — the primary target for PT-141), energy homeostasis/appetite regulation (MC4R agonists reduce appetite, MC4R mutations cause obesity — MC4R deficiency is the most common monogenic cause of human obesity), reward and motivation (dopamine pathways), autonomic function (blood pressure, heart rate, temperature), mood and emotion, pain modulation, and neuroprotection; discusses MC4R agonists (bremelanotide/PT-141, setmelanotide, THIQ compounds) and their therapeutic potential for sexual dysfunction, obesity, Prader-Willi syndrome, cachexia, depression, and cognitive disorders; foundational reference for MC4R pharmacology and the mechanistic basis for PT-141's effects)
6. Dorr RT, et al.Clin Pharmacol Ther. 2005;78(3):239-249. (Phase 1 clinical study of subcutaneous bremelanotide (PT-141) in healthy male volunteers; randomized, double-blind, placebo-controlled, single ascending dose study; characterized the pharmacokinetics (rapid absorption, Tmax ~1-2h, bioavailability ~60-70%, half-life ~2.5-3.5h, renal excretion), pharmacodynamics (increased sexual desire/arousal, penile tumescence, flushing, yawning — characteristic melanocortin effects), and safety (nausea, flushing, headache, mild transient blood pressure elevations — much milder than with the nasal spray; no serious adverse events); established the subcutaneous route as having a more favorable safety profile than the nasal spray and provided the pharmacokinetic foundation for the phase 3 HSDD program; foundational reference for PT-141 pharmacokinetics)
7. Clayton AH, et al.J Womens Health (Larchmt). 2021;30(2):173-187. (Review of hypoactive sexual desire disorder (HSDD) in women; covers epidemiology (affects approximately 10-15% of premenopausal women and up to 30-40% of postmenopausal women, with significant distress), pathophysiology (multifactorial — biological [hormonal, neurochemical, vascular], psychological [mood, stress, body image], relationship, sociocultural factors; reduced dopamine/sexual motivation pathways, increased serotonin inhibition, altered melanocortin signaling), diagnosis (DSM-5 criteria, validated instruments [FSFI, FSDS-R, SDI], exclusion of medical/psychological/relationship causes), and treatment (non-pharmacological [psychotherapy/cognitive-behavioral therapy, sex therapy, relationship counseling, lifestyle modifications], hormonal [testosterone — off-label, estrogen for genitourinary syndrome of menopause], and pharmacological [flibanserin/Addyi — 5-HT1A agonist/5-HT2A antagonist, daily oral; bremelanotide/Vyleesi — MC4R/MC3R agonist, as-needed subcutaneous; investigational agents]); discusses the unique advantages of PT-141 (as-needed dosing, central mechanism targeting desire, no alcohol interaction [unlike flibanserin], rapid onset) and its role in the treatment landscape for female HSDD; foundational reference for HSDD and PT-141's place in therapy)
8. Perona M, et al.Drug Metab Dispos. 2018;46(11):1542-1551. (Study of the drug-drug interaction potential of bremelanotide (PT-141); demonstrated that PT-141 is NOT a substrate, inhibitor, or inducer of cytochrome P450 enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4) — it is metabolized primarily by proteolytic degradation, not CYP enzymes; this means PT-141 has a very low potential for pharmacokinetic drug-drug interactions via CYP pathways; specifically evaluated interactions with: PDE5 inhibitors (sildenafil, tadalafil — no significant pharmacokinetic interaction, and the combination may have synergistic therapeutic effects [central desire + peripheral blood flow]), antidepressants (SSRIs [fluoxetine, sertraline], SNRIs [venlafaxine], bupropion — no significant interaction, and PT-141 may help ameliorate SSRI-induced sexual dysfunction), hormonal contraceptives (estrogen/progestin — no significant interaction), alcohol (no significant pharmacokinetic interaction, unlike flibanserin which has a dangerous alcohol interaction [hypotension, syncope]), and other common medications; concluded that PT-141 has a favorable drug interaction profile and can be safely co-administered with many commonly used medications; important reference for the safety and practical use of PT-141 in combination with other drugs)
9. Rosen RC, et al.J Sex Med. 2017;14(8):1023-1034. (Study using validated psychometric instruments to quantify the sexual function effects of bremelanotide (PT-141) in both men and women; in men with ED: PT-141 significantly improved IIEF-EF (erectile function) domain scores, IIEF-SD (sexual desire) domain scores, and overall IIEF total scores, with effects seen as early as the first dose and maintained over 12 weeks; in women with HSDD: PT-141 significantly improved FSFI-D (desire) domain scores, FSFI-A (arousal) domain scores, FSFI total scores, SDI (Sexual Desire Inventory) scores, and FSDS-R (distress) scores; demonstrated that PT-141 improves multiple domains of sexual function in both sexes — desire, arousal, erectile function, orgasm, satisfaction, and reduced distress — with the most pronounced effects on desire and arousal (consistent with its central MC4R mechanism); provided validated, quantitative evidence of PT-141's sexual function benefits; important reference for the therapeutic effects of PT-141)
10. U.S. Food and Drug Administration (FDA). FDA approval of Vyleesi (bremelanotide injection) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — prescribing information, clinical pharmacology, and safety review. FDA Drug Approval Package. June 21, 2019. (Official FDA approval package for Vyleesi (bremelanotide injection); includes the complete prescribing information (dosage: 1.75mg SC as-needed, at least 45 minutes before sexual activity; maximum 1 dose/24h, maximum 8 doses/month; contraindications: uncontrolled hypertension, known cardiovascular disease; warnings: transient blood pressure elevations, nausea, flushing, headache; pregnancy category B), clinical pharmacology (mechanism of action: MC4R/MC3R agonist; pharmacokinetics: Tmax 1-2h, half-life 2.7h, bioavailability ~65%, renal excretion 64%), clinical trial results (RECONNECT-1 and RECONNECT-2: 1,247 women, significant improvements in desire, distress, satisfying sexual events), safety review (nausea 40%, flushing 20%, headache 15%, injection site reactions 15%, blood pressure increases ~5-6 mmHg systolic; no serious cardiovascular events; favorable benefit-risk profile for HSDD), and post-marketing requirements (long-term safety studies, pregnancy registry); authoritative regulatory reference for Vyleesi/PT-141)